EP0478689A4 - Human monoclonal antibodies to hiv-1 mn? gp 120 - Google Patents

Human monoclonal antibodies to hiv-1 mn? gp 120

Info

Publication number: EP0478689A4
Authority: EP; European Patent Office
Prior art keywords: hiv; monoclonal antibodies; human monoclonal; human; antibodies
Prior art date: 1989-06-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP19900910991

Other versions

EP0478689A1 (en

Inventor

Charles F. Scott Jr.

Helen F. Carson

Mary E. White-Scharf

Sandra Silver

James R. Rusche

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-05

Filing date

1990-06-05

Publication date

1993-06-16

1990-06-05 Application filed by Individual filed Critical Individual

1992-04-08 Publication of EP0478689A1 publication Critical patent/EP0478689A1/en

1993-06-16 Publication of EP0478689A4 publication Critical patent/EP0478689A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Zoology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Plant Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)

EP19900910991 1989-06-05 1990-06-05 Human monoclonal antibodies to hiv-1 mn? gp 120 Withdrawn EP0478689A4 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US36154189A	1989-06-05	1989-06-05
US361541		1989-06-05
US43128189A	1989-11-03	1989-11-03
US431281		1989-11-03

Publications (2)

Publication Number	Publication Date
EP0478689A1 EP0478689A1 (en)	1992-04-08
EP0478689A4 true EP0478689A4 (en)	1993-06-16

Family

ID=27001330

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19900910991 Withdrawn EP0478689A4 (en)	1989-06-05	1990-06-05	Human monoclonal antibodies to hiv-1 mn? gp 120

Country Status (7)

Country	Link
EP (1)	EP0478689A4 (en)
JP (1)	JPH05506561A (en)
AU (1)	AU6036690A (en)
CA (1)	CA2058630A1 (en)
IL (1)	IL94624A0 (en)
PT (1)	PT94276A (en)
WO (1)	WO1990015078A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5712373A (en) *	1990-07-02	1998-01-27	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
JP2989862B2 (en) *	1990-07-02	1999-12-13	財団法人化学及血清療法研究所	Monoclonal antibody
CA2094713A1 (en) *	1990-10-26	1992-04-27	Shermaine A. Tilley	Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
IT1244529B (en) *	1991-01-30	1994-07-15	Ist Superiore Sanita	SYNTHETIC PEPTIDES SUITABLE TO ENHANCE THE INFECTIVITY OF THE HIV-1 VIRUS
WO1994004574A1 (en) *	1991-08-22	1994-03-03	Nissin Shokuhin Kabushiki Kaisha	Hiv immunotherapeutics
EP0554446B1 (en) *	1991-08-22	1998-11-04	Nissin Shokuhin Kabushiki Kaisha	Monoclonal antibodies useful in therapy of HIV-1 infection
SK116294A3 (en) *	1992-04-01	1996-11-06	Merck & Co Inc	Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv
DK0728015T3 (en)	1992-06-18	2006-07-17	Creagen Inc	Combinatorial polypeptide antigens
EP0588750A3 (en) *	1992-08-05	1995-01-11	Cigb	Method for the production of recombinant polypeptides bearing epitopes from different hiv isolates, and their uses as immunogens and in the detection of antibodies against hiv.
WO1994020632A1 (en) *	1993-03-11	1994-09-15	Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute	Anti-hiv monoclonal antibody
US5618922A (en) *	1994-07-25	1997-04-08	Nissin Shokuhin Kabushiki Kaisha	NM03 antibody materials and methods
EP1595959B1 (en) *	2003-02-20	2015-01-21	The Chemo-Sero-Therapeutic Research Institute	Method for enhancing efficacy of a monoclonal antibody preparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0339504A2 (en) *	1988-04-26	1989-11-02	The Du Pont Merck Pharmaceutical Company	Human immunodeficiency virus (HIV) env-coded peptide capable of eliciting HIV-inhibiting antibodies in mammals
WO1990003984A1 (en) *	1988-10-03	1990-04-19	Repligen Corporation	Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
WO1991006575A1 (en) *	1989-11-03	1991-05-16	Repligen Corporation	Hiv-1 specific human monoclonal antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4755457A (en) *	1985-02-05	1988-07-05	Robert Guroff Marjorie	Method for detecting HTLV-III neutralizing antibodies in sera
JP2520464B2 (en) *	1987-05-29	1996-07-31	タノツクス・バイオシステムズ・インコーポレーテツド	Monoclonal antibody that neutralizes HIV-1

1990
- 1990-06-05 EP EP19900910991 patent/EP0478689A4/en not_active Withdrawn
- 1990-06-05 JP JP90510360A patent/JPH05506561A/en active Pending
- 1990-06-05 CA CA002058630A patent/CA2058630A1/en not_active Abandoned
- 1990-06-05 WO PCT/US1990/003157 patent/WO1990015078A1/en not_active Application Discontinuation
- 1990-06-05 PT PT199094276A patent/PT94276A/en not_active Application Discontinuation
- 1990-06-05 AU AU60366/90A patent/AU6036690A/en not_active Abandoned
- 1990-06-05 IL IL94624A patent/IL94624A0/en unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0339504A2 (en) *	1988-04-26	1989-11-02	The Du Pont Merck Pharmaceutical Company	Human immunodeficiency virus (HIV) env-coded peptide capable of eliciting HIV-inhibiting antibodies in mammals
WO1990003984A1 (en) *	1988-10-03	1990-04-19	Repligen Corporation	Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
WO1991006575A1 (en) *	1989-11-03	1991-05-16	Repligen Corporation	Hiv-1 specific human monoclonal antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9015078A1 *

Also Published As

Publication number	Publication date
WO1990015078A1 (en)	1990-12-13
PT94276A (en)	1991-02-08
EP0478689A1 (en)	1992-04-08
AU6036690A (en)	1991-01-07
JPH05506561A (en)	1993-09-30
CA2058630A1 (en)	1990-12-06
IL94624A0 (en)	1991-04-15

Publication	Publication Date	Title
GB8905669D0 (en)	1989-04-26	Modified antibodies
GB2196634B (en)	1991-05-15	Monoclonal antibodies to hiv and related peptides
GB2186592B (en)	1990-08-01	Cross-protective human monoclonal antibody compositions
EP0478689A4 (en)	1993-06-16	Human monoclonal antibodies to hiv-1 mn? gp 120
GB8608068D0 (en)	1986-05-08	Monoclonal antibodies
EP0285511A3 (en)	1988-12-28	Monoclonal antibodies and their uses
KR960001503B1 (en)	1996-01-31	Method for rdetecting antibodies to human immunodeficiency virus
EP0418347A4 (en)	1994-12-14	Human monoclonal antibodies to human immunodeficiency virus
ZA904305B (en)	1991-05-29	Human monoclonal antibodies to hiv-1 mn gp 120
IL86960A0 (en)	1988-12-30	Preparation of human monoclonal antibodies
GB8927389D0 (en)	1990-01-31	Monoclonal antibodies
GB8610202D0 (en)	1986-05-29	Monoclonal antibodies
GB8610203D0 (en)	1986-05-29	Monoclonal antibodies
EP0252768A3 (en)	1989-08-23	Anti-lafora body monoclonal antibody
IE891095L (en)	1989-10-07	Human monoclonal antibodies
GB9318912D0 (en)	1993-10-27	Humanised antibodies
ZA87863B (en)	1987-09-30	Cross-protective human monoclonal antibody compositions
IE892311L (en)	1990-01-18	Improved monoclonal antibodies
IE890065L (en)	1989-07-12	Antigen antibody conjugate
IE870536L (en)	1987-09-04	Compositions comprising monoclonal antibodies
GB8907377D0 (en)	1989-05-17	Antibodies
IE892557L (en)	1990-02-12	Monoclonal antibodies
IE891298L (en)	1989-10-22	Monoclonal antibodies
IE890064L (en)	1989-07-12	Monoclonal antibodies
GB8705550D0 (en)	1987-04-15	Monoclonal antibodies to urokinase

Legal Events

Date	Code	Title	Description
1992-02-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1992-04-08	17P	Request for examination filed	Effective date: 19911205
1992-04-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE
1993-06-16	A4	Supplementary search report drawn up and despatched	Effective date: 19930427
1993-06-16	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE
1995-08-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
1995-10-11	17Q	First examination report despatched	Effective date: 19950829
1995-10-18	18W	Application withdrawn	Withdrawal date: 19950810